GenSight Biologics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Laurence Rodriguez

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	2.8yrs
Board average tenure	9.9yrs

Recent management updates

Recent updates

Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?

Dec 22

GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate

Jun 14

GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?

May 10

Analysts Expect Breakeven For GenSight Biologics S.A. (EPA:SIGHT) Before Long

Feb 02

A Quick Analysis On GenSight Biologics' (EPA:SIGHT) CEO Salary

Dec 09

CEO

Laurence Rodriguez (56 yo)

less than a year

Tenure

Mrs. Laurence Rodriguez is Chief Executive Officer of GenSight Biologics S.A. from December 21, 2023 and has been its Director since January 12, 2024. Ms. Rodriguez has many years of experience in the life...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Laurence Rodriguez	CEO & Director	less than a year	no data	no data
Jose-Alain Sahel	Scientific Founder	no data	no data	no data
Botond Roska	Scientific Founder & Chairman of Scientific Advisory Board	no data	no data	no data
Luk Vandenberghe	Scientific Founder & Member of Scientific Advisory Board	no data	no data	no data
Serge Picaud	Scientific Founder & Member of Scientific Advisory Board	no data	no data	no data
Constance Cepko	Scientific Founder & Member of Scientific Advisory Board	no data	no data	no data
Ivan Tortet	Chief Financial Officer	less than a year	no data	no data
Scott Jeffers	Chief Technical Officer	2.4yrs	no data	no data
Barrett Katz	Consultant	6.9yrs	no data	no data
Magali Taiël	Chief Medical Officer	4.9yrs	no data	no data
Marion Ghibaudo	Chief Technical Officer of Medical Device	3.3yrs	no data	no data

2.8yrs

Average Tenure

58yo

Average Age

Experienced Management: SIGHT's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Laurence Rodriguez	CEO & Director	less than a year	no data	no data
Jose-Alain Sahel	Scientific Founder	12.4yrs	no data	no data
Botond Roska	Scientific Founder & Chairman of Scientific Advisory Board	12.4yrs	no data	no data
Luk Vandenberghe	Scientific Founder & Member of Scientific Advisory Board	12.4yrs	no data	no data
Serge Picaud	Scientific Founder & Member of Scientific Advisory Board	12.4yrs	no data	no data
Constance Cepko	Scientific Founder & Member of Scientific Advisory Board	12.4yrs	no data	no data
Cédric Moreau	Representative Director	5.3yrs	no data	no data
Ernst Bamberg	Member of Scientific Advisory Board	12.4yrs	no data	no data
Maritza McIntyre	Independent Director	5.3yrs	€33.75k	no data
Simone Seiter	Independent Director	7.4yrs	€33.75k	no data
Elsy Boglioli	Independent Director	4yrs	€45.00k	no data
Francoise de Craecker	Independent Director	3.4yrs	€45.00k	no data

9.9yrs

Average Tenure

56.5yo

Average Age

Experienced Board: SIGHT's board of directors are considered experienced (9.9 years average tenure).

GenSight Biologics Management

Management criteria checks 2/4

Key information

Recent management updates

Gensight Biologics S.A. Appoints William Monteith to Its Board of Directors

Gensight Biologics S.A. Announces CFO Changes

GenSight Biologics Announces Board Changes

GenSight Biologics S.A. Announces CEO Changes

Insufficient new directors

GenSight Biologics Appoints Philippe Motté as Senior Vice President, Regulatory and Quality

Recent updates

New major risk - Share price stability

GenSight Biologics S.A. Provides Business Update

Gensight Biologics S.A. Appoints William Monteith to Its Board of Directors

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues exceed analyst expectations

GenSight Biologics S.A. to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Revenue and earnings growth

GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024

New major risk - Shareholder dilution

GenSight Biologics S.A. has completed a Follow-on Equity Offering in the amount of €5 million.

Gensight Biologics S.A. Announces CFO Changes

New minor risk - Shareholder dilution

GenSight Biologics Announces Board Changes

GenSight Biologics S.A. Announces CEO Changes

Consensus revenue estimates decrease by 12%, EPS upgraded

Gensight Biologics S.A. Confirms Second Successful GMP Batch of Lumevoq

GenSight Biologics S.A. Announces Preliminary Assay Indicating Successful Manufacture of Second LUMEVOQ® GMP Batch

GenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ

GenSight Biologics Announces Successful Manufacture of LUMEVOQ GMP Batch

First half 2023 earnings released: €0.26 loss per share (vs €0.23 loss in 1H 2022)

Consensus revenue estimates decrease by 17%, EPS upgraded

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast to breakeven in 2025

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals

Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?

GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy

GenSight Biologics Announces Publication of Results of LUMEVOQ® REFLECT Pivotal Clinical Trial in Peer-Reviewed Journals

Price target decreased to €10.67

Insufficient new directors

Is GenSight Biologics S.A. (EPA:SIGHT) Trading At A 39% Discount?

GenSight Biologics S.A Announces Successful Completion of LUMEVOQ Engineering Batch Validating Implemented Corrective Actions

GenSight Biologics Appoints Philippe Motté as Senior Vice President, Regulatory and Quality

Health Check: How Prudently Does GenSight Biologics (EPA:SIGHT) Use Debt?

Insufficient new directors

First half 2022 earnings released

Insufficient new directors

GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology

Price target decreased to €12.50

GenSight Biologics Grants Six-Month Extension in LUMEVOQ® European Regulatory Review

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 19%

Price target decreased to €12.50

GenSight Biologics S.A. Provides Update on LUMEVOQ® Manufacturing Timeline

Gensight Biologics to Present Reflect Phase III Data with LUMEVOQ® At the NANOS 2022 Meeting

GenSight Biologics Appoints Sissel Rodahl as Senior Vice-President of Commercial Operations to Lead the Launch of Lumevoq® in Europe

GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy

Forecast to breakeven in 2024

GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection

Price target decreased to €15.00

Price target decreased to €16.00

GenSight Biologics S.A. Announces Positive Data Safety Monitoring Board Review of Pioneer Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa

GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials

GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ

Rock star Growth Puts GenSight Biologics (EPA:SIGHT) In A Position To Use Debt

First half 2021 earnings released: €0.19 loss per share (vs €0.43 loss in 1H 2020)

GenSight Biologics S.A. Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use in France

Gensight Biologics Reports Topline Results from Reflect Phase III Clinical Trial, Confirming Lumevoq® Efficacy Including Better Efficacy with Bilateral Treatment

GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate

GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ versus Natural History in Frontiers in Neurology

GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?

GenSight Biologics S.A. Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye

Full year 2020 earnings released: €0.97 loss per share (vs €1.09 loss in FY 2019)

Full year 2020 earnings released: €0.97 loss per share (vs €1.08 loss in FY 2019)

Earnings beat expectations, revenue disappoints

New 90-day high: €9.26